Inivata_CMYK_Logo.jpg
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
11 janv. 2022 07h00 HE | Inivata
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...
Inivata_CMYK_Logo.jpg
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
28 avr. 2021 07h00 HE | Inivata
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...
Inivata_CMYK_Logo.jpg
Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer
18 déc. 2020 07h00 HE | Inivata
Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer Research Collaboration to be led by the University of Southampton and along with...
Inivata_CMYK_Logo.jpg
Inivata to Present Data at AACR Virtual Annual Meeting Highlighting Capabilities and Clinical Application of RaDaR™ Assay
22 juin 2020 09h32 HE | Inivata
Inivata to Present Data at AACR Virtual Annual Meeting Highlighting Capabilities and Clinical Application of RaDaR™ Assay Personalized assay for detection of residual disease and recurrence...